SEC Form 10-Q Summary
Filing/entity note: The supplied filing is for Neuralstem, Inc., not Palisade Bio, Inc. It covers the quarter and six months ended June 30, 2012, and was filed August 9, 2012. The financial statements are unaudited and prepared under U.S. GAAP.
Business Context and Reporting Period
Neuralstem was a development-stage biotechnology company focused on human neural stem-cell therapies and small-molecule compounds for central nervous system diseases. Its principal programs included Phase I trials for amyotrophic lateral sclerosis and NSI-189 for major depressive disorder. The company had no commercial product revenue and remained dependent on equity financing, grants, and research contracts.
- ALS Phase I trial: 17 patients treated as of the filing date; the company anticipated treating 18 patients.
- NSI-189 Phase Ib trial: first patient dosed in June 2012; 24 patients were planned.
- Spinal-cord-injury IND remained on clinical hold.
- The initial year of the Department of Defense subcontract with Loma Linda University was completed in the second quarter of 2012.
Financial Metrics
| Metric | Three months ended June 30, 2012 | Six months ended June 30, 2012 | Comparable prior period |
|---|---|---|---|
| Revenue | $78,125 | $234,375 | $0 |
| Operating expenses | $2,461,380 | $5,080,846 | $3,668,868 / $7,205,371 |
| Operating loss | $(2,383,255) | $(4,846,471) | $(3,668,868) / $(7,205,371) |
| Net loss | $(2,376,381) | $(4,829,162) | $(3,648,725) / $(6,750,527) |
| Loss per share | $(0.04) | $(0.09) | $(0.08) / $(0.14) |
| Cash used in operating activities | Not separately presented | $(4,539,288) | $(4,500,092) |
| Cash and cash equivalents | Not applicable | $2,539,534 at June 30, 2012 | $6,141,843 at June 30, 2011 |
- Research and development expense was $3.02 million for the six months, down 21% year over year.
- General and administrative expense was $1.98 million, down 40%, primarily due to lower stock compensation, legal fees, bonuses, and salaries.
- The company reported no meaningful gross margin because revenue consisted of limited subcontract services and there was no commercial product revenue.
- Total liabilities were $1.47 million, all classified as current; the filing does not disclose material long-term debt.
- Working capital surplus was approximately $1.36 million, and stockholders’ equity was $2.49 million.
- Cash provided by financing activities was $4.88 million, primarily from a February 2012 registered direct offering of common stock and warrants.
- Shares outstanding increased to 54.1 million at June 30, 2012, from 48.7 million at December 31, 2011. Outstanding options, restricted stock units, and warrants created substantial potential dilution.
Material Changes Versus the Prior Comparable Period
- Revenue increased from zero to $78,125 for the quarter and $234,375 year to date, entirely from the Department of Defense subcontract; the contract expired in the second quarter.
- Quarterly operating expenses declined 33%, while year-to-date operating expenses declined 29%.
- Net loss improved by $1.27 million for the quarter and $1.92 million for the six-month period, primarily due to lower operating expenses.
- Year-to-date cash used in operations was broadly stable despite the lower net loss, at $4.54 million versus $4.50 million.
- Cash at June 30, 2012 was 59% below the June 30, 2011 balance, despite the 2012 equity financing.
- Prior-year other income included a $250,000 litigation settlement and a $161,809 warrant fair-value gain; neither item recurred in 2012.
- The CFO resigned in April 2012. The CEO became interim CFO and principal accounting officer, and the company engaged third-party financial reporting consultants.
Guidance, Outlook, Risks, and Unusual Items
- Management estimated monthly operating cash burn of approximately $700,000 and stated that available cash, expected income, and anticipated financing proceeds were expected to fund current activities through at least June 30, 2013, although activities and personnel might need to be reduced.
- Management expected additional operating losses and did not expect profitability in the next several years.
- Additional financing was considered necessary for ongoing research, clinical trials, regulatory activities, and general operations. Future financing might be unavailable or available only on unfavorable terms.
- The company’s principal risks included failure of clinical trials, FDA or other regulatory delays, dependence on third-party manufacturers and clinical research organizations, intellectual-property disputes, limited commercial experience, competition, and substantial dilution from future securities issuances.
- Litigation with StemCells, Inc. involving patent infringement, validity, standing, and related claims remained unresolved. The court had stayed other matters pending resolution of the standing issue; the filing did not quantify a probable loss.
- The DOD program’s continuation beyond the completed initial year was uncertain because of budget considerations.
- All outstanding derivative warrant liabilities had been eliminated by the end of the comparable 2011 period; warrants issued in 2012 were classified as equity.
Important Facts for Investors to Verify
- Confirm that the intended issuer is Neuralstem, Inc., because the supplied filing does not relate to Palisade Bio, Inc.
- Reconcile the stated liquidity runway with the $2.54 million cash balance, approximately $700,000 monthly cash burn, and the company’s dependence on future financing.
- Review the status, safety data, and planned completion of the ALS and NSI-189 Phase I trials, as well as the clinical hold on the spinal-cord-injury program.
- Assess the effect of the expired DOD subcontract and the uncertainty regarding renewal funding.
- Review outstanding options, warrants, and reserved shares for potential dilution.
- Monitor the StemCells patent litigation and any related legal or intellectual-property exposure.
- Evaluate the transition to an interim CFO and the effectiveness of related financial reporting controls.